TD Securities analyst Aaron Macneil downgrades Shawcor (TSX:SCL) from Buy to Hold and raises the price target from C$12 to C$13.
AstraZeneca’s Combination Cancer Drug For Advanced Breast Cancer Study Flunks Late-Stage Trial
AstraZeneca announced that the CAPItello-290 Phase 3 trial for Truqap (capivasertib) combined with paclitaxel in advanced or metastatic triple-negative breast cancer did not meet primary endpoints for overall survival.